42 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
2
Design, Palladium-Catalyzed Synthesis, and Biological Investigation of 2-Substituted 3-Aroylquinolin-4(1H)-ones as Inhibitors of the Hedgehog Signaling Pathway.
Sapienza University of Rome
27
Design, Synthesis, and Pharmacological Evaluation of 2-(2,5-Dimethyl-5,6,7,8-tetrahydroquinolin-8-yl)-N-aryl Propanamides as Novel Smoothened (Smo) Antagonists.
University of Chinese Academy of Sciences
21
Design, synthesis and biological characterization of a new class of osteogenic (1H)-quinolone derivatives.
University of Siena
18
Discovery of a 6-(pyridin-3-yl)benzo[d]thiazole template for optimization of hedgehog and PI3K/AKT/mTOR dual inhibitors.
Soochow University
22
Orally active 7-substituted (4-benzylphthalazin-1-yl)-2-methylpiperazin-1-yl]nicotinonitriles as active-site inhibitors of sphingosine 1-phosphate lyase for the treatment of multiple sclerosis.
Novartis Institutes For Biomedical Research
30
Scaffold hopping approach to a new series of smoothened antagonists.
Soochow University
4
Synthesis and biological evaluation of novel benzamide derivatives as potent smoothened antagonists.
Sichuan University
4
Identification of a novel Smoothened antagonist that potently suppresses Hedgehog signaling.
Duke University Medical Center
14
Design, synthesis, and structure-activity-relationship of phenyl imidazoles as potent Smoothened antagonists.
Genomics Institute of The Novartis Research Foundation
31
Macrocyclic Hedgehog Pathway Inhibitors: Optimization of Cellular Activity and Mode of Action Studies.
TBA
25
Discovery of novel hedgehog antagonists from cell-based screening: Isosteric modification of p38 bisamides as potent inhibitors of SMO.
AstraZeneca
12
Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened.
TBA
32
Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity.
University of Siena
28
Identification and structure-activity relationships of ortho-biphenyl carboxamides as potent Smoothened antagonists inhibiting the Hedgehog signaling pathway.
Novartis Institutes For Biomedical Research
20
Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit.
Amgen
85
Identification of a series of 4-[3-(quinolin-2-yl)-1,2,4-oxadiazol-5-yl]piperazinyl ureas as potent smoothened antagonist hedgehog pathway inhibitors.
Merck Research Laboratories
38
N-(2-alkylaminoethyl)-4-(1,2,4-oxadiazol-5-yl)piperazine-1-carboxamides as highly potent smoothened antagonists.
Merck Research Laboratories
17
Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 2.
Merck Research Laboratories
57
Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, part 1.
Merck Research Laboratories
1
Purmorphamine activates the Hedgehog pathway by targeting Smoothened.
Stanford University School of Medicine
27
Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines.
Amgen
1
Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926).
Infinity Pharmaceuticals
35
1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity.
Novartis Institutes For Biomedical Research
5
Discovery of N-substituted-2-oxoindolin benzoylhydrazines as c-MET/SMO modulators in EGFRi-resistant non-small cell lung cancer.
University of Campania
9
Current approaches and strategies to identify Hedgehog signaling pathway inhibitors for cancer therapy.
Peking Union Medical College
1
Tetracyclic Steroids Bearing a Bicyclo[4.4.1] Ring System as Potent Antiosteoporosis Agents from the Deep-Sea-Derived Fungus
Third Institute of Oceanography
11
Design, synthesis and biological evaluation of novel 4-aminopiperidine derivatives as SMO/ERK dual inhibitors.
China Pharmaceutical University
13
Medulloblastoma drugs in development: Current leads, trials and drawbacks.
University of Connecticut
24
Elucidation of Distinct Modular Assemblies of Smoothened Receptor by Bitopic Ligand Measurement.
Shanghaitech University
5
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
Southern Medical University
27
Heteroarylamide smoothened inhibitors: Discovery of N-[2,4-dimethyl-5-(1-methylimidazol-4-yl)phenyl]-4-(2-pyridylmethoxy)benzamide (AZD8542) and N-[5-(1H-imidazol-2-yl)-2,4-dimethyl-phenyl]-4-(2- pyridylmethoxy)benzamide (AZD7254).
AstraZeneca
14
Colocalization Strategy Unveils an Underside Binding Site in the Transmembrane Domain of Smoothened Receptor.
Shanghaitech University
28
Structural optimization on a virtual screening hit of smoothened receptor.
Soochow University
31
Structure-Activity Relationships for Itraconazole-Based Triazolone Analogues as Hedgehog Pathway Inhibitors.
University of Connecticut
35
Discovery of N-[(1-aryl-1H-indazol-5-yl)methyl]amides derivatives as smoothened antagonists for inhibition of the hedgehog pathway.
Irbm-Merck Research Laboratories Rome
15
Synergistic inhibition of the Hedgehog pathway by newly designed Smo and Gli antagonists bearing the isoflavone scaffold.
Sapienza University of Rome
7
Discovery and characterization of a potent Wnt and hedgehog signaling pathways dual inhibitor.
Soochow University
37
Discovery of potent and novel smoothened antagonists via structure-based virtual screening and biological assays.
Soochow University
4
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
University of Campania Luigi Vanvitelli
